Associated Papers
Association of a common variant at 10q26 and benign prostatic hyperplasia aggressiveness in han chinese descent.
Gu X et al.
Biochemistry Research International, 2013
[V89L polymorphism of the testosterone 5-alpha-reductase II gene and prognostic factors of prostate cancer].
Tong M et al.
Zhonghua Nan Ke Xue = National Journal of Andrology, 2010
Polymorphisms in genes regulating androgen activity among prostate cancer low-risk Inuit men and high-risk Scandinavians.
Giwercman C et al.
International Journal of Andrology, 2008
Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer.
Cunningham JM et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2007
The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
Giwercman YL et al.
European Urology, 2005
Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2.
Loukola A et al.
European Journal of Human Genetics : Ejhg, 2004
Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.
Kakinuma H et al.
Prostate Cancer and Prostatic Diseases, 2004
The V89L polymorphism in the 5-alpha-reductase type 2 gene and risk of breast cancer.
van Gils CH et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2003
A review of genetic polymorphisms and prostate cancer risk.
Coughlin SS et al.
Annals of Epidemiology, 2002
Longer (TA)n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men.
Rajender S et al.
Journal of Andrology, 0